William A. See

William A. See

Auto-generated profile, based on publicly available information

William A. See

Department of Urology, Medical College of Wisconsin, Milwaukee, WI, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2007 in BMC Urology
Verified
Journal Article
Open access
PDF file
ASAnna R Smither
Anna R Smither
MGMichael L Guralnick
Michael L Guralnick
NDNancy B Davis
Nancy B Davis
WSWilliam A See
William A See
Background: Urinary incontinence (UI) following radical prostatectomy is a well-recognized risk of the surgery. In most patients post-operative UI improves over time. To date, there is limited objective, quantitative data on the natural history of the resolution of post-prostatectomy UI. The purpose of this study was to define the natural history of post radical prostatectomy incontinence using an objective quantitative tool, the 1-hour standard pad test. Methods: 203 consecutive patients underwent radical prostatectomy by a single surgeon between 03/98 & 08/03. A standardized 1-hour pad test was administered at subsequent postoperative clinic visits. The gram weight of urine loss was recorded and subdivided into four groups defined according to the grams of urine loss: minimal (1, 50 g). Patients were evaluated: at 2 weeks (catheter removal), 6 weeks, 18 weeks, 30 weeks, 42 weeks and 54 weeks. The data set was analyzed for average urine loss as well as grams of urine loss at each time point, the percentage of patients and the distribution of patients in each category. Results: Mean follow up was 118 weeks. The majority of patients experienced incontinence immediately after catheter removal at 2 weeks that gradually improved with time. While continued improvement was noted to 1 year, most patients who achieved continence did so by 18 weeks post-op. Conclusion: While the majority of patients experience mild to severe UI immediately following catheter removal, there is a rapid decrease in leaked weight during the first 18 weeks following RRP. Patients continue to improve out to 1 year with greater than 90% having minimal leakage by International Continence Society criteria.

2 August 2006 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
WSWilliam A. See
William A. See
CTChris J. Tyrrell
Chris J. Tyrrell
OGon behalf of the CASODEX™ Early Prostate Cancer Trialists’ Group
on behalf of the CASODEX™ Early Prostate Cancer Trialists’ Group

29 December 2015 in IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control
Verified
Journal Article
Closed access
SPSarah K. Patch
Sarah K. Patch
DHDavid Hull
David Hull
WSWilliam A. See
William A. See
GHGeorge W. Hanson
George W. Hanson
Thermoacoustics has the potential to provide quantitative images of intrinsic tissue properties, most notably electrical conductivity in Siemens/meter, much as shear wave elastography provides tissue stiffness in kilopascal. Although thermoacoustic imaging with optical excitation has been commercialized for small animals, it has not yet made the transition to clinic for whole organ imaging in humans. The purpose of this work was to develop and validate specifications for a clinical ultrasound array for quantitative whole organ thermoacoustic imaging. Imaging a large organ requires exciting thermoacoustic pulses throughout the volume and broadband detection of those pulses because tomographic image reconstruction preserves frequency content. Applying the half-wavelength limit to a $200 \text{-}\upmu \text{m}$ inclusion inside a 7.5-cm diameter organ requires measurement sensitivity to frequencies ranging from 4 MHz to 10 kHz, respectively. A dual-transducer system utilizing a P4-1 array connected to a Verasonics V1 system as well as a focused single-element transducer sensitive to lower frequencies was developed. Very high-frequency (VHF) irradiation generated thermoacoustic pulses throughout a $6 \times 6 \times 5\ \text{cm}^{3}$ volume. In the VHF regime, electrical conductivity drives thermoacoustic signal production. Simultaneous acquisition of thermoacoustic pulses by both transducers enabled comparison of transducer performance. Data from the clinical array generated a stack of 96 images with a separation of 0.3 mm, whereas the single-element transducer imaged only in a single plane. In-plane resolution and quantitative accuracy were quantified at isocenter. The array provided volumetric imaging capability with superior resolution whereas the single-element transducer provided superior quantitative accuracy in axial images. Combining axial images from both transducers preserved resolution of the P4-1 array and improved image contrast. Neither transducer was sensitive to frequencies below 50 kHz, resulting in a dc offset and low-frequency shading over fields of view exceeding 15 mm. Fresh human prostates were imaged ex vivo and volumetric reconstructions reveal structures rarely seen in diagnostic images. In conclusion, quantitative whole-organ thermoacoustic tomography will be feasible by sparsely interspersing transducer elements sensitive to the low end of the ultrasonic range.

27 May 2009 in BJU International
Verified
Journal Article
Open access
PDF file
WSWilliam A. See
William A. See
GZGuangjian Zhang
Guangjian Zhang
FCFanghong Chen
Fanghong Chen
YCYanli Cao
Yanli Cao
PLPeter Langenstroer
Peter Langenstroer
JSJay Sandlow
Jay Sandlow
OBJECTIVE: To evaluate the ability of bacille‐Calmette Guèrin (BCG) to induce caspase‐independent cell death and release the necrosis‐associated chemokine high molecular group box protein 1 (HMGB1) from urothelial carcinoma (UC) cells; a correlative clinical trial determined if BCG treatment resulted in increased urinary levels of HMGB1. PATIENTS, MATERIALS AND METHODS: The human UC cell lines 253 J and T24 were pretreated with apoptosis inhibitors, exposed to BCG, and cell viability and ultrastructural changes measured. HMGB1 levels were assessed in cell culture supernatant after BCG treatment. The expression/function of HMGB1 receptors on the UC cell lines was determined by reverse transcription‐polymerse chain reaction and the ability of exogenous HMGB1 to activate nuclear factor (NF)‐κB signalling assessed. An HMGB1 enzyme‐linked immunosorbent assay was used to measure HMGB1 levels in urine obtained from BCG‐treated patients. RESULTS: Inhibition of apoptotic pathways failed to inhibit BCG‐induced cell death in UC cells. Electron microscopy showed BCG‐dependent ultrastructural changes consistent with cellular necrosis. BCG exposure resulted in a binary increase in cell culture supernatant levels of HMGB1. UCs expressed multiple HMGB1 receptors. Treatment of UCs with HMGB1 activated NF‐κB. In the clinical setting, six of seven patients had increased urinary levels of HMGB1 at 24 h after BCG treatment. CONCLUSIONS: BCG causes direct cytotoxicity in a subpopulation of UC cells. This cytotoxicity is caspase‐independent and associated with ultrastructural changes and cellular protein release (HMGB1), characteristic of necrosis. Urinary levels of HMGB1 can be elevated in patients after BCG treatment. The expression and function of HMGB1 receptors in UC cells, coupled with the known role of HMGB1 on the host immune response, suggest a role for necrosis and HMGB1 release in the antitumour effect of BCG.

1 January 2014 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
GSGopitkumar Shah
Gopitkumar Shah
GZGuangjian Zhang
Guangjian Zhang
FCFanghong Chen
Fanghong Chen
YCYanLi Cao
YanLi Cao
BKBalaraman Kalyanaraman
Balaraman Kalyanaraman
WSWilliam A. See
William A. See

1 August 2002
Verified
Journal Article
Closed access
FCFang-Hong Chen
Fang-Hong Chen
SCScott A Crist
Scott A Crist
GZGuang-Jian Zhang
Guang-Jian Zhang
YIYoshiki Iwamoto
Yoshiki Iwamoto
WSWilliam A See
William A See